Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of CGT9486 Monotherapy in Advanced Systemic Mastocytosis
2021-001010-10Phase 2Active
- Sponsor
- Cogent Biosciences
- Start
- Aug 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bezuclastinib in systemic mastocytosis (SM) and Aggressive Systemic Mastocytosis (ASM), sponsored by Cogent Biosciences. Primary endpoint: Dose Optimization (Part 1). Started Aug 2021; status: active.
02
Drugs
bezuclastinib
03
Conditions
systemic mastocytosis (SM)Aggressive Systemic Mastocytosis (ASM)
Beyond the preview
Go deeper on 2021-001010-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001010-10.